Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Cooperative Group
Institut Gustave Roussy
Other Non-Commercial Sponsor
Innovative Therapies For Children with Cancer Consortium
Summary
Participants in this study will be allocated to a treatment that specifically targets a biological abnormality identified via a biopsy. The possible treatment groups are as follows; (1)If the tumor overexpresses EGFR without PTEN loss of expression, patients may receive erlotinib or dasatinib allocated by randomization; (2) If the tumor shows loss of PTEN expression without EGFR overexpression, patients may receive everolimus or dasatinib allocated by randomisation; (3) If the tumor shows both EGFR overexpression and loss of PTEN expression, patients may receive erlotinib, everolimus or dasatinib by randomisation; (4) If the tumor shows neither EGFR overexpression nor loss of PTEN expression (a very rare situation in our experience), patients will receive dasatinib; (5) If the biopsy assessment is not contributive, the treatment will be allocated by randomisation between erlotinib, everolimus and dasatinib.